Inside the $9B Gut Economy:
How Microbiome Science is Rewriting Healthcare’s Future
Once a niche field, the gut microbiome is now a $1.6B market poised to reach ~$8.9B by 2034.
Backed by FDA-approved therapeutics, precision diagnostics, and AI-engineered probiotics, it’s reshaping how we understand metabolism, immunity, and chronic disease.
From AI-driven probiotics to GLP-1-linked breakthroughs, our first ever 37- page Scope Forward Market Research Report maps the science, startups, and clinical pathways defining this new frontier in gastroenterology.
What You’ll Learn:
- Market shifts: How the microbiome is evolving from lab research to mainstream medicine—on track for $8.9B by 2034.
- Clinical impact: Why gastroenterologists are uniquely positioned to lead the microbiome revolution.
- Startup intelligence: The innovators, investors, and FDA-approved breakthroughs shaping the next decade.
Why It Matters
Microbiome science isn’t just about gut health anymore—it’s redefining how we diagnose, treat, and prevent disease. This report connects the dots between science, business, and clinical opportunity in one clear, data-driven view.
An essential read for gastroenterologists, investors, and healthcare leaders ready to stay ahead of the curve.